We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+17.84%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.95B
AUM Growth
+$102M
Cap. Flow
-$18.2M
Cap. Flow %
-0.46%
Top 10 Hldgs %
61.14%
Holding
68
New
17
Increased
8
Reduced
4
Closed
9

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$133M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$99.5M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$83.8M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$72.8M
5
ADAP
Adaptimmune Therapeutics
ADAP
+$33.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$435M
2
ARGX icon
argenx
ARGX
+$115M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$35.6M
4
SYRE icon
Spyre Therapeutics
SYRE
+$19.1M
5
RVMD icon
Revolution Medicines
RVMD
+$3.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
2 Miscellaneous 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$668M 16.89%
11,357,425
+184,357
+2% +$11.8M
PRTA icon
2
Prothena Corp
PRTA
$479M
$287M 7.26%
11,584,280
– –
ARVN icon
3
Arvinas
ARVN
$600M
$278M 7.02%
6,726,491
– –
SRPT icon
4
Sarepta Therapeutics
SRPT
$2.2B
$249M 6.29%
1,919,835
+1,086,928
+130% +$133M
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$9B
$195M 4.92%
4,155,375
+2,142,858
+106% +$83.8M
LKFT
6
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$185M 4.69%
5,756,268
– –
ANAB icon
7
AnaptysBio
ANAB
$1.67B
$169M 4.28%
7,521,024
– –
ZYME icon
8
Zymeworks
ZYME
$2.02B
$141M 3.58%
13,437,473
– –
KURA icon
9
Kura Oncology
KURA
$1.13B
$124M 3.13%
5,806,871
– –
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$15.9B
$122M 3.09%
1,013,952
– –
XNCR icon
11
Xencor
XNCR
$1.94B
$118M 2.98%
5,330,416
+47,900
+0.9% +$1.03M
ACAD icon
12
Acadia Pharmaceuticals
ACAD
$5.02B
$111M 2.8%
5,991,479
– –
TNGX icon
13
Tango Therapeutics
TNGX
$3.94B
$106M 2.68%
13,330,736
– –
IMNM icon
14
Immunome
IMNM
$3.13B
$95.7M 2.42%
3,879,415
– –
CRSP icon
15
CRISPR Therapeutics
CRSP
$5.58B
$94.7M 2.4%
+1,389,276
New +$99.5M
MRSN
16
DELISTED
Mersana Therapeutics
MRSN
$86.8M 2.19%
774,588
– –
MORF
17
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$83.9M 2.12%
2,384,384
+2,173,122
+1,029% +$72.8M
NUVB icon
18
Nuvation Bio
NUVB
$2.34B
$69.9M 1.77%
19,209,643
– –
NGNE icon
19
Neurogene
NGNE
$732M
$64.7M 1.64%
1,271,342
– –
CNTA
20
DELISTED
Centessa Pharmaceuticals
CNTA
$63.5M 1.61%
5,618,779
– –
ORIC icon
21
Oric Pharmaceuticals
ORIC
$1.37B
$47M 1.19%
3,418,068
– –
ADAP
22
DELISTED
Adaptimmune Therapeutics
ADAP
$43.3M 1.1%
+27,404,070
New +$33.1M
TCRX icon
23
TScan Therapeutics
TCRX
$51.1M
$39.7M 1%
5,000,000
– –
VYGR icon
24
Voyager Therapeutics
VYGR
$218M
$36.5M 0.92%
3,917,546
+66,039
+2% +$558K
THRD
25
DELISTED
Third Harmonic Bio
THRD
$30M 0.76%
3,182,444
– –
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2024 Portfolio in Review

As of Q1 2024, EcoR1 Capital held 68 positions worth $3.95B, up 2.7% from $3.85B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

EcoR1 Capital's Q1 2024 filing shows 17 new, 8 increased, 4 reduced and 9 closed positions. Its largest new stake was CRISPR Therapeutics: 1,389,276 shares worth $94.7M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $435M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q1 2024 buy was CRISPR Therapeutics: 1,389,276 shares worth $94.7M.
  • EcoR1 Capital added most to Sarepta Therapeutics in Q1 2024, an estimated $133M increase.
  • EcoR1 Capital's biggest Q1 2024 reduction was Edgewise Therapeutics, cutting an estimated $35.6M.
  • EcoR1 Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $435M.
  • EcoR1 Capital's ten largest holdings make up 61% of its $3.95B portfolio in Q1 2024.
  • EcoR1 Capital opened 17 new positions and closed 9 in Q1 2024.
  • EcoR1 Capital's portfolio value rose 2.7% quarter-over-quarter to $3.95B.

Based on EcoR1 Capital's 13F filing for Q1 2024, filed 15 May 2024.